Selected Bibliography

• Annette Pluddemann, Christopher P Price, Matthew Thompson, Jane Wolstenholme and Carl Heneghan (2011): Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin. - Br J Gen Pract, 61(583):139-40.
• Oliver Rivero-Arias, Alastair Gray and Jane Wolstenholme (2010): Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. - Cost Eff Resour Alloc, 8:6.
• Oliver Rivero-Arias, Melissa Ouellet, Alastair Gray, Jane Wolstenholme, Peter M Rothwell and Ramon Luengo-Fernandez (2010): Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. - Med Decis Making, 30(3):341-54.
• Rosa Legood, Jane Wolstenholme and Alastair Gray (2009): From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap. - Health Policy, 89(2):193-200.
• Oliver Rivero-Arias, Jane Wolstenholme, Alastair Gray, Andrew J Molyneux, Richard S C Kerr, Julia A Yarnold and Mary Sneade (2009): The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm Trial. - J Neurol, 256(3):364-73.
• Jane Wolstenholme, Oliver Rivero-Arias, Alastair Gray, Andrew J Molyneux, Richard S C Kerr, Julia A Yarnold and Mary Sneade (2008): Treatment pathways, resource use, and costs of endovascular coiling versus surgical clipping after aSAH. - Stroke, 39(1):111-9.
• Andrew Briggs, Borislava Mihaylova, Mark Sculpher, Alistair Hall, Jane Wolstenholme, Maarten Simoons, Jaap Deckers, Roberto Ferrari, Willem J Remme, Michel Bertrand and Kim Fox (2007): Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. - Heart, 93(9):1081-6.
• Rosa Legood, Alastair Gray, Jane Wolstenholme and Sue Moss (2006): Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. - BMJ, 332(7533):79-85.
• E J Frew, J L Wolstenholme and D K Whynes (2005): Eliciting relative preferences for two methods of colorectal cancer screening. - Eur J Cancer Care (Engl), 14(2):124-31.
• Rosa Legood, Alastair M Gray, Cedric Mahe, Jane Wolstenholme, Kasturi Jayant, Bhagwan M Nene, Surendra S Shastri, Sylla G Malvi, Richard Muwonge, Atul M Budukh and Rengaswamy Sankaranarayanan (2005): Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. - Int J Cancer, 117(6):981-7.
• David K Whynes, Emma J Frew and Jane L Wolstenholme (2005): Willingness-to-pay and demand curves: a comparison of results obtained using different elicitation formats. - Int J Health Care Finance Econ, 5(4):369-86.
• Emma J Frew, Jane L Wolstenholme and David K Whynes (2004): Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats. - Health Policy, 68(3):289-98.
• David K Whynes, Jane L Wolstenholme and Emma Frew (2004): Evidence of range bias in contingent valuation payment scales. - Health Econ, 13(2):183-90.
• David K Whynes, Emma Frew and Jane L Wolstenholme (2003): A comparison of two methods for eliciting contingent valuations of colorectal cancer screening. - J Health Econ, 22(4):555-74.
• Emma J Frew, David K Whynes and Jane L Wolstenholme (2003): Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. - Med Decis Making, 23(2):150-9.
• Andrew Briggs, Taane Clark, Jane Wolstenholme and Philip Clarke (2003): Missing... presumed at random: cost-analysis of incomplete data. - Health Econ, 12(5):377-92.
• DK Whynes, JL Wolstenholme and EJ Frew (2003): Evidence of range bias in contingent valuation payment scales. - Health Economics.
• J Wolstenholme, P Fenn, A Gray, J Keene, R Jacoby and T Hope (2002): Estimating the relationship between disease progression and cost of care in dementia. - Br J Psychiatry, 181:36-42.
• E Frew, J Wolstenholme and D Whynes (2001): Mass population screening for colorectal cancer: factors influencing subjects' choice of screening test. - J Health Serv Res Policy, 6(2):85-91.
• E J Frew, V Hammersley, J Wolstenholme and D K Whynes (2001): Collaborating with a primary care-based research network. - J Eval Clin Pract, 7(3):339-42.
• S Petrou and J Wolstenholme (2000): A review of alternative approaches to healthcare resource allocation. - Pharmacoeconomics, 18(1):33-43.
• P D Hayes, A J Lloyd, N Lennard, J L Wolstenholme, N J London, P R Bell and A R Naylor (2000): Transcranial Doppler-directed Dextran-40 therapy is a cost-effective method of preventing carotid thrombosis after carotid endarterectomy. - Eur J Vasc Endovasc Surg, 19(1):56-61.
• E Frew, J L Wolstenholme, W Atkin and D K Whynes (1999): Estimating time and travel costs incurred in clinic based screening: flexible sigmoidoscopy screening for colorectal cancer. - J Med Screen, 6(3):119-23.
• P Dolan, D J Torgerson and J Wolstenholme (1999): Costs of breast cancer treatment in the United Kingdom. - Breast, 8(4):205-7.
• J L Wolstenholme and D K Whynes (1999): The hospital costs of treating lung cancer in the United Kingdom. - Br J Cancer, 80(1-2):215-8.
• J L Wolstenholme and D K Whynes (1998): Stage-specific treatment costs for cervical cancer in the United Kingdom. - Eur J Cancer, 34(12):1889-93.